149 related articles for article (PubMed ID: 28864978)
1. Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Hasegawa K; Kagabu M; Mizuno M; Oda K; Aoki D; Mabuchi S; Kamiura S; Yamaguchi S; Aoki Y; Saito T; Yunokawa M; Takehara K; Okamoto A; Ochiai K; Kimura T
Invest New Drugs; 2017 Dec; 35(6):800-812. PubMed ID: 28864978
[TBL] [Abstract][Full Text] [Related]
2. Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.
Myers AP; Konstantinopoulos PA; Barry WT; Luo W; Broaddus RR; Makker V; Drapkin R; Liu J; Doyle A; Horowitz NS; Meric-Bernstam F; Birrer M; Aghajanian C; Coleman RL; Mills GB; Cantley LC; Matulonis UA; Westin SN
Int J Cancer; 2020 Jul; 147(2):413-422. PubMed ID: 31714586
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.
Vergote IB; Lund B; Peen U; Umajuridze Z; Mau-Sorensen M; Kranich A; Van Nieuwenhuysen E; Haslund C; Nottrup T; Han SN; Concin N; Unger TJ; Chai Y; Au N; Rashal T; Joshi A; Crochiere M; Landesman Y; Shah J; Shacham S; Kauffman M; Mirza MR
Gynecol Oncol; 2020 Feb; 156(2):308-314. PubMed ID: 31822399
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of perifosine monotherapy in patients with recurrent or refractory neuroblastoma.
Matsumoto K; Shichino H; Kawamoto H; Kosaka Y; Chin M; Kato K; Mugishima H
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28521076
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
Kaley TJ; Panageas KS; Mellinghoff IK; Nolan C; Gavrilovic IT; DeAngelis LM; Abrey LE; Holland EC; Lassman AB
J Neurooncol; 2019 Sep; 144(2):403-407. PubMed ID: 31325145
[TBL] [Abstract][Full Text] [Related]
6. Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
Passarelli A; Carbone V; Pignata S; Mazzeo R; Lorusso D; Scambia G; Canova S; Di Palma T; Tasca G; Mantiero M; Naglieri E; Andreetta C; Rauso M; Brunetti AE; Laera L; Abeni C; Scandurra G; Gambaro AR; Pastore A; Bengala C; Gunnellini M; Farolfi A; Spinello M; Bartoletti M
Gynecol Oncol; 2024 Apr; 183():61-67. PubMed ID: 38518529
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
Argiris A; Cohen E; Karrison T; Esparaz B; Mauer A; Ansari R; Wong S; Lu Y; Pins M; Dancey J; Vokes E
Cancer Biol Ther; 2006 Jul; 5(7):766-70. PubMed ID: 16760642
[TBL] [Abstract][Full Text] [Related]
8. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in
Banerji U; Dean EJ; Pérez-Fidalgo JA; Batist G; Bedard PL; You B; Westin SN; Kabos P; Garrett MD; Tall M; Ambrose H; Barrett JC; Carr TH; Cheung SYA; Corcoran C; Cullberg M; Davies BR; de Bruin EC; Elvin P; Foxley A; Lawrence P; Lindemann JPO; Maudsley R; Pass M; Rowlands V; Rugman P; Schiavon G; Yates J; Schellens JHM
Clin Cancer Res; 2018 May; 24(9):2050-2059. PubMed ID: 29066505
[No Abstract] [Full Text] [Related]
9. Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation.
Morii Y; Tsubaki M; Takeda T; Otubo R; Seki S; Yamatomo Y; Imano M; Satou T; Shimomura K; Nishida S
Eur J Pharmacol; 2021 May; 898():173957. PubMed ID: 33662352
[TBL] [Abstract][Full Text] [Related]
10. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.
Chee KG; Longmate J; Quinn DI; Chatta G; Pinski J; Twardowski P; Pan CX; Cambio A; Evans CP; Gandara DR; Lara PN
Clin Genitourin Cancer; 2007 Dec; 5(7):433-7. PubMed ID: 18272025
[TBL] [Abstract][Full Text] [Related]
11. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
12. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with
Jhaveri K; Chang MT; Juric D; Saura C; Gambardella V; Melnyk A; Patel MR; Ribrag V; Ma CX; Aljumaily R; Bedard PL; Sachdev JC; Dunn L; Won H; Bond J; Jones S; Savage HM; Scaltriti M; Wilson TR; Wei MC; Hyman DM
Clin Cancer Res; 2021 Jan; 27(2):447-459. PubMed ID: 33148674
[TBL] [Abstract][Full Text] [Related]
13. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
Lee JB; Jung M; Beom SH; Kim GM; Kim HR; Choi HJ; Sohn JH; Ahn JB; Rha SY; Chung HC
Invest New Drugs; 2021 Oct; 39(5):1366-1374. PubMed ID: 33723724
[TBL] [Abstract][Full Text] [Related]
16. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Krop IE; Mayer IA; Ganju V; Dickler M; Johnston S; Morales S; Yardley DA; Melichar B; Forero-Torres A; Lee SC; de Boer R; Petrakova K; Vallentin S; Perez EA; Piccart M; Ellis M; Winer E; Gendreau S; Derynck M; Lackner M; Levy G; Qiu J; He J; Schmid P
Lancet Oncol; 2016 Jun; 17(6):811-821. PubMed ID: 27155741
[TBL] [Abstract][Full Text] [Related]
17. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
18. Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies.
Eskander RN; Tewari KS
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):847-58. PubMed ID: 25301678
[TBL] [Abstract][Full Text] [Related]
19. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.
Kushner BH; Cheung NV; Modak S; Becher OJ; Basu EM; Roberts SS; Kramer K; Dunkel IJ
Int J Cancer; 2017 Jan; 140(2):480-484. PubMed ID: 27649927
[TBL] [Abstract][Full Text] [Related]
20. Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.
Engel JB; Honig A; Schönhals T; Weidler C; Häusler S; Krockenberger M; Grunewald TG; Dombrowski Y; Rieger L; Dietl J; Wischhusen J
Eur J Obstet Gynecol Reprod Biol; 2008 Nov; 141(1):64-9. PubMed ID: 18687514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
